Mesoblast: Half Yearly Report and Accounts (including Appendix 4D)
Filed with ASX · · 118 pages · English
Yes No Yes No TABLE OF CONTENTS Page Foreword 3 Currency of Presentation and Certain Defined Terms 3 Forward-Looking Statements 3 Financial Statements 5 Management’s Discussion and Analysis of Financial Condition and Results of Operations 28 Risk Factors 55 Signatures 89 Exhibits 90 Page 2 QUARTERLY REPORT ON FORM 6-K (INCORPORATING THE HALF-YEAR REPORT) FOR THE THREE AND SIX MONTHS ENDED DECEMBER
In the deck
Earlier from Mesoblast
- MSB Therapy Shows Benefit In First Cohort Of RA Patients
- Phase 3 Heart Failure Trial Size Substantially Reduced
- US Govt Grants for Further Development of Stem Cell Products
- USA FDA Clears Phase 2 Trial For Cervical Spinal Fusion
- Type 2 Diabetes Trial Results Published In Diabetes Care
Later from Mesoblast
- Increased Survival Using MSB Cells In Children With aGVHD
- GVHD Product Launched In Japan
- Key US Patent Granted For Treatment Of Rheumatoid Arthritis
- Circulation Publishes Improved Outcomes with Mesoblast Cells
- Mesoblast Receives $5.05m for Stem Cell Pipeline Development
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast